Healthcare Global Enterprises quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	695	613	+13.4%
EBITDA	122	108	+13.4%
EBITDA margin	17.6%	17.6%	0.0 pts
Profit before tax	24.1	11.2	+114.4%
Net profit	16.5	6.0	+175.3%
EPS	₹0.92	₹0.34	+170.6%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	695	652	633	647	613	585	558	554	526	495	470	487	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	12.1	13.1	2.5	2.6	6.8	10.2	5.7	11.1	8.8	5.1	6.1	3.4
	707	665	636	649	620	595	563	565	534	500	476	490
	187	181	173	181	166	154	152	149	136	125	113	122
	−8.0	−4.0	3.1	−4.1	−4.5	−0.1	−2.7	−4.4	−2.5	−1.9	1.3	−1.2
	105	92.5	94.2	94.2	97.8	92.8	90.2	85.3	85.2	76.9	77.3	77.2
	39.9	42.7	44.8	43.6	45.5	44.2	40.7	36.0	33.7	26.8	29.5	26.9
	70.4	62.8	60.7	62.8	57.9	58.1	56.5	49.7	47.0	46.0	44.2	43.2
	290	258	253	252	246	233	231	222	216	203	200	204
	683	633	629	630	609	582	567	537	515	475	465	472
	122	125	110	123	108	106	87.4	102	90.9	92.0	78.6	84.6
	51.8	62.3	49.0	60.5	49.9	47.7	30.8	52.5	43.9	46.1	34.5	41.4
Profit
	24.1	32.6	6.7	19.5	11.2	13.7	−4.2	27.7	19.0	24.3	11.1	17.9
	0.0	−31.9	−12.7	0.0	0.0	0.0	0.0	0.0	0.0	3.9	0.0	0.0
	24.1	0.7	−6.0	19.5	11.2	13.7	−4.2	27.7	19.0	28.2	11.1	17.9
	8.7	−1.6	4.4	8.1	8.9	12.6	−2.6	11.1	7.7	7.6	8.7	8.5
	−0.1	−1.2	−2.6	−8.9	−3.0	−5.7	−8.4	−4.1	−2.3	−2.8	−1.1	−1.4
	8.6	−2.8	1.8	−0.8	5.9	6.9	−11.1	7.0	5.4	4.8	7.6	7.1
	0.9	0.5	−0.1	0.3	0.7	−0.1	0.9	−0.0	−0.0	0.1	−0.0	−0.0
	16.5	4.0	−7.9	20.7	6.0	6.8	7.8	20.7	13.6	23.5	3.4	10.8
	15.5	3.5	−7.9	20.4	5.3	6.9	6.9	20.7	13.6	23.4	3.4	10.8
	0.5	1.7	2.1	0.6	0.3	0.2	0.6	0.4	0.6	3.7	−1.3	−1.4
	17.0	5.7	−5.8	21.2	6.2	7.0	8.3	21.0	14.3	27.1	2.2	9.4
	13.8	2.2	−9.4	16.3	4.8	7.4	7.0	18.0	12.1	21.3	5.7	13.6
	2.7	1.9	1.5	4.4	1.2	−0.6	0.8	2.7	1.6	2.2	−2.3	−2.8
Per share
	₹0.92	₹0.15	−₹0.68	₹1.16	₹0.34	₹0.53	₹0.50	₹1.29	₹0.87	₹1.53	₹0.41	₹0.98
	₹0.92	₹0.15	−₹0.68	₹1.16	₹0.34	₹0.52	₹0.49	₹1.28	₹0.86	₹1.51	₹0.41	₹0.97
Other comprehensive income — detail
	0.5	1.7	2.1	0.6	0.3	0.2	—	—	—	—	—	—
	0.0	0.1	0.6	0.1	0.0	0.2	−0.1	0.0	0.0	−0.7	0.0	0.0
	0.0	0.0	0.0	0.1	0.0	0.0	—	—	—	—	—	—
	0.5	1.5	1.5	0.5	0.3	0.0	0.7	0.4	0.6	4.3	−1.3	−1.4
	14.2	4.3	−7.9	17.1	4.9	7.6	7.6	18.4	12.5	24.7	4.6	12.3
	2.7	1.4	2.1	4.2	1.3	−0.6	0.8	2.7	1.8	2.4	−2.4	−2.8
Per share — as-filed variants
	₹0.92	₹0.15	−₹0.68	₹1.16	₹0.34	₹0.53	₹0.50	₹1.29	₹0.87	₹1.53	₹0.41	₹0.98
	₹0.92	₹0.15	−₹0.68	₹1.16	₹0.34	₹0.52	₹0.49	₹1.28	₹0.86	₹1.51	₹0.41	₹0.97
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	516	476	457	470	451	431	408	409	392	372	356	366
	74.3%	72.9%	72.1%	72.6%	73.6%	73.7%	73.3%	73.9%	74.7%	75.2%	75.8%	75.2%
Adjusted (ex-exceptional items) — derived
	24.1	32.6	6.7	19.5	11.2	13.7	−4.2	27.7	19.0	24.3	11.1	17.9
	0.0	−31.9	−12.7	0.0	0.0	0.0	0.0	0.0	0.0	3.9	0.0	0.0
	16.5	36.0	4.8	20.7	6.0	6.8	7.8	20.7	13.6	20.2	3.4	10.8
	₹0.92	₹1.33	₹0.41	₹1.16	₹0.34	₹0.53	₹0.50	₹1.29	₹0.87	₹1.32	₹0.41	₹0.98

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

HCG₹585.60

Healthcare Global Enterprises Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAPOLLOHOSP FORTIS RAINBOW JLHL CORONA MARKSANS METROPOLIS PARKHOSPSMcap ₹8,427 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	486.9	469.9	494.6	525.6	553.5	557.6	585.2	613.2	646.9	633.1	652.3	695.1
Other Income	3.4	6.1	5.1	8.8	11.1	5.7	10.2	6.8	2.6	2.5	13.1	12.1
Total Income	490.3	475.9	499.7	534.4	564.7	563.2	595.4	620.0	649.5	635.5	665.4	707.2
Expenses
+ Purchases of Stock-in-Trade	122.1	112.6	124.7	135.7	148.6	151.8	154.1	166.3	181.2	173.4	180.7	186.8
+ Changes in Inventories	-1.2	1.3	-1.9	-2.5	-4.4	-2.7	-0.1	-4.5	-4.1	3.1	-4.0	-8.0
+ Employee Benefit Expense	77.2	77.3	76.9	85.2	85.3	90.2	92.8	97.8	94.2	94.2	92.5	104.5
+ Finance Costs	26.9	29.5	26.8	33.7	36.0	40.7	44.2	45.5	43.6	44.8	42.7	39.9
+ Depreciation & Amortisation	43.2	44.2	46.0	47.0	49.7	56.5	58.1	57.9	62.8	60.7	62.8	70.4
+ Other Expenses	204.3	200.0	203.0	216.3	221.8	230.8	232.6	245.7	252.2	252.7	258.1	289.5
Total Expenses	472.4	464.9	475.4	515.4	537.0	567.4	581.7	608.8	630.0	628.9	632.8	683.1
EBITDA	84.6	78.6	92.0	90.9	102.3	87.4	105.7	107.8	123.3	109.6	125.1	122.3
EBIT	41.4	34.5	46.1	43.9	52.5	30.8	47.7	49.9	60.5	49.0	62.3	51.8
Profit
PBT before Exceptional Items	17.9	11.1	24.3	19.0	27.7	-4.2	13.7	11.2	19.5	6.7	32.6	24.1
+ Exceptional Items	0.0	0.0	3.9	0.0	0.0	0.0	0.0	0.0	0.0	-12.7	-31.9	0.0
Pretax Income	17.9	11.1	28.2	19.0	27.7	-4.2	13.7	11.2	19.5	-6.0	0.7	24.1
+ Current Tax	8.5	8.7	7.6	7.7	11.1	-2.6	12.6	8.9	8.1	4.4	-1.6	8.7
+ Deferred Tax	-1.4	-1.1	-2.8	-2.3	-4.1	-8.4	-5.7	-3.0	-8.9	-2.6	-1.2	-0.1
Tax Expense	7.1	7.6	4.8	5.4	7.0	-11.1	6.9	5.9	-0.8	1.8	-2.8	8.6
+ Share of Associates & JVs	-0.0	-0.0	0.1	-0.0	-0.0	0.9	-0.1	0.7	0.3	-0.1	0.5	0.9
Net Income	10.8	3.4	23.5	13.6	20.7	7.8	6.8	6.0	20.7	-7.9	4.0	16.5
+ Net Income — Continuing Ops	10.8	3.4	23.4	13.6	20.7	6.9	6.9	5.3	20.4	-7.9	3.5	15.5
+ Other Comprehensive Income	-1.4	-1.3	3.7	0.6	0.4	0.6	0.2	0.3	0.6	2.1	1.7	0.5
Total Comprehensive Income	9.4	2.2	27.1	14.3	21.0	8.3	7.0	6.2	21.2	-5.8	5.7	17.0
Net Income to Common	13.6	5.7	21.3	12.1	18.0	7.0	7.4	4.8	16.3	-9.4	2.2	13.8
Minority Interest	-2.8	-2.3	2.2	1.6	2.7	0.8	-0.6	1.2	4.4	1.5	1.9	2.7
Per Share
Basic EPS	0.98	0.41	1.53	0.87	1.29	0.50	0.53	0.34	1.16	-0.68	0.15	0.92
Diluted EPS	0.97	0.41	1.51	0.86	1.28	0.49	0.52	0.34	1.16	-0.68	0.15	0.92
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	0.2	0.3	0.6	2.1	1.7	0.5
+ Items NOT to be Reclassified to P&L	0.0	0.0	-0.7	0.0	0.0	-0.1	0.2	0.0	0.1	0.6	0.1	0.0
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	0.0	0.0	0.1	0.0	0.0	0.0
+ Items to be Reclassified to P&L	-1.4	-1.3	4.3	0.6	0.4	0.7	0.0	0.3	0.5	1.5	1.5	0.5
Comprehensive Income — Owners of Parent	12.3	4.6	24.7	12.5	18.4	7.6	7.6	4.9	17.1	-7.9	4.3	14.2
Comprehensive Income — Non-controlling Interests	-2.8	-2.4	2.4	1.8	2.7	0.8	-0.6	1.3	4.2	2.1	1.4	2.7
Per Share — as-filed variants
Basic EPS — Continuing Operations	0.98	0.41	1.53	0.87	1.29	0.50	0.53	0.34	1.16	-0.68	0.15	0.92
Diluted EPS — Continuing Operations	0.97	0.41	1.51	0.86	1.28	0.49	0.52	0.34	1.16	-0.68	0.15	0.92
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	366.1	356.0	371.9	392.4	409.3	408.4	431.1	451.3	469.7	456.5	475.6	516.3
Gross Margin %	75.18	75.75	75.19	74.65	73.94	73.26	73.68	73.60	72.61	72.11	72.91	74.28
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	17.9	11.1	24.3	19.0	27.7	-4.2	13.7	11.2	19.5	6.7	32.6	24.1
− Exceptional Items (reconciliation)	0.0	0.0	3.9	0.0	0.0	0.0	0.0	0.0	0.0	-12.7	-31.9	0.0
Net Income Adj (tax-effected)	10.8	3.4	20.2	13.6	20.7	7.8	6.8	6.0	20.7	4.8	36.0	16.5
EPS Adj	0.98	0.41	1.32	0.87	1.29	0.50	0.53	0.34	1.16	0.41	1.33	0.92
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	139.3	139.3	139.3	139.4	139.4	139.4	139.4	139.4	141.0	141.0	149.3	149.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Healthcare Global Enterprises Q2 FY27 results date

Healthcare Global Enterprises (NSE: HCG) will announce its Q2 FY27 results (July–September 2026) on Thursday, 5 November 2026, according to the board-meeting notice it filed on 13 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹13.8 crore, up 189.9% from ₹4.8 crore in Q1 FY26 and up 534.6% from ₹2.2 crore in Q4 FY26. Revenue from operations was ₹695 crore, up 13.4% year on year and up 6.6% from the previous quarter.

Board-meeting notice filed: 13 October 2026
Q2 FY26 results (a year earlier): 12 November 2025
Q1 FY27 results (the latest): 6 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 5 November 2026Thursday · notice filed 13 Oct
Q1 FY27 net profit: ₹13.8 Cr+189.9% vs Q1 FY26+534.6% vs Q4 FY26
Q1 FY27 revenue: ₹695 Cr+13.4% vs Q1 FY26+6.6% vs Q4 FY26
Q1 FY27 operating margin: 7.5%−0.7 pts vs Q1 FY26−2.1 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹16.3 CrRevenue ₹647 Cr
Q1 FY27 EPS (basic): ₹0.92

Questions

When will Healthcare Global Enterprises announce its Q2 FY27 results?

On 5 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 13 October 2026). Last year it reported Q2 FY26 on 12 November 2025.

What will Healthcare Global Enterprises' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹16.3 crore and revenue from operations ₹647 crore. The latest quarter, Q1 FY27, had a net profit of ₹13.8 crore and revenue of ₹695 crore.

What was Healthcare Global Enterprises' revenue in FY26?

Revenue from operations was ₹2,545 crore in FY26 (April 2025–March 2026), up 14.5% from ₹2,223 crore in FY25. It was ₹1,912 crore in FY24 and ₹1,694 crore in FY23: up 50.2% over three years, 14.5% a year on average.

What were Healthcare Global Enterprises' Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹13.8 crore, up 189.9% from ₹4.8 crore in Q1 FY26 and up 534.6% from ₹2.2 crore in Q4 FY26. Revenue from operations was ₹695 crore, up 13.4% year on year and up 6.6% from the previous quarter.

How has Healthcare Global Enterprises' profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: a profit of ₹16.3 crore in Q2 FY26, a loss of ₹9.4 crore in Q3 FY26, a profit of ₹2.2 crore in Q4 FY26 and a profit of ₹13.8 crore in Q1 FY27. That is a combined profit of ₹22.8 crore over the four quarters, down 38.6% from ₹37.1 crore in the four quarters before. Revenue from operations: ₹647 crore, ₹633 crore, ₹652 crore and ₹695 crore.

What was Healthcare Global Enterprises' net profit in FY26?

Consolidated net profit attributable to shareholders was ₹13.8 crore in FY26 (April 2025–March 2026), down 69.0% from ₹44.4 crore in FY25. It was ₹48.1 crore in FY24 and ₹29.3 crore in FY23: down 53.1% over three years, an average fall of 22.3% a year.

Where do these Healthcare Global Enterprises figures come from?

From Healthcare Global Enterprises' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.